Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

843
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
843
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

1.4K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.4K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

4.1K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
4.1K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

5.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.1K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

4.8K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.8K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

2.0K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Three cases of hypertension-related events who were not treated as 'white-coat hypertension'.

Blood pressure monitoring·2026
Same author

Validity of risk stratification of JSH 2025 guideline based on hypertensive retinal changes.

Hypertension research : official journal of the Japanese Society of Hypertension·2026
Same author

Successful Immunosuppressive Therapy for Aseptic Abscess Syndrome Presenting with a Fever of Unknown Origin.

Internal medicine (Tokyo, Japan)·2026
Same author

Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study.

Cardiovascular diabetology·2023
Same author

Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial.

Journal of cardiology·2022
Same author

Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial.

European heart journal. Cardiovascular pharmacotherapy·2022

Related Experiment Video

Updated: Mar 30, 2026

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.8K

Lung Disease and Hypertension.

Yuki Imaizumi1, Kazuo Eguchi1, Kazuomi Kario1

  • 1Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.

Pulse (Basel, Switzerland)
|November 21, 2015
PubMed
Summary

Chronic obstructive pulmonary disease (COPD) patients face increased cardiovascular risks due to systemic inflammation and sympathetic overactivity. This review explores the links between lung disease, hypertension, and cardiovascular morbidity, alongside treatment strategies.

Keywords:
Cardiovascular diseaseChronic obstructive pulmonary diseaseInflammationSympathetic overactivity

More Related Videos

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

26.2K
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.6K

Related Experiment Videos

Last Updated: Mar 30, 2026

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.8K
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

26.2K
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.6K

Area of Science:

  • Pulmonary Medicine
  • Cardiology
  • Systemic Inflammation

Background:

  • Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a systemic inflammatory condition.
  • COPD is associated with heightened risks of cardiovascular diseases, including hypertension.
  • Inflammation in COPD may contribute to sympathetic nervous system overactivity.

Purpose of the Study:

  • To review the association between chronic lung disease and hypertension risk.
  • To examine cardiovascular morbidity in COPD patients.
  • To discuss underlying mechanisms and therapeutic strategies for cardiovascular conditions in COPD.

Main Methods:

  • Literature review of studies on COPD, hypertension, and cardiovascular disease.
  • Analysis of the role of systemic inflammation and sympathetic overactivity.
  • Synthesis of current therapeutic approaches.

Main Results:

  • Airflow limitation in COPD predicts future hypertension and cardiovascular events.
  • Systemic inflammation is a key factor linking COPD to cardiovascular risks.
  • Sympathetic overactivity is implicated in the pathophysiology.

Conclusions:

  • COPD significantly elevates the risk of cardiovascular diseases and hypertension.
  • Understanding the inflammatory and sympathetic pathways is crucial for management.
  • Integrated therapeutic strategies are needed for cardiovascular conditions in COPD patients.